Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F
Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F
Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| GRCL | 10.25 | +0.01 | +0.05% |
| Gracell Biotechnologies Inc ADR | |||